News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
|Title||Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J|
|Journal||Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association|
|Date Published||2013 Oct 22|
Hyperphosphataemia in patients with advanced chronic kidney disease (CKD) is associated with adverse outcomes, including vascular calcification and higher mortality rates. While phosphate lowering is an integral aspect of CKD management, the efficacy and safety of phosphate binders in a contemporary cohort of Chinese haemodialysis patients (who have different genetics and dietary patterns than other populations) has not been previously described. Moreover, sparse data are available on strategies for optimal dose titration when transitioning from a calcium-based to a polymer-based phosphate binder.
|Alternate Journal||Nephrol. Dial. Transplant.|